Navigation Links
CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
Date:8/31/2010

CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up -- STOCKHOLM, August 31, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up

 

STOCKHOLM, August 31, 2010 /PRNewswire/ --

- The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today at European Society of Cardiology in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER(R) Sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety and were published earlier this year in "JACC: Cardiovascular Interventions". The 85-year-old patient was the first-ever patient to be treated with a CYPHER(R) stent and made history by undergoing the longest term follow-up, ten years later. The patient was the first person to be treated with a CYPHER(R) stent in the non-randomized, in-human trial.

The patient, who was treated in 1999 with the CYPHER(R) stent at the age of 75 after her coronary angiography showed a significant, single, de novo lesion in the proximal left anterior descending (LAD) artery, under-went further invasive follow-up revealing a sustained anti-proliferative effect of the CYPHER(R) stent by both angiography and IVUS examination in 2009. The patient also underwent an optical coherence tomography (OCT) assessment which revealed a complete coverage of over 90% of the analyzed struts. This 10-Year follow-up of the first-ever patient to be treated with CYPHER(R) took place continuing a tradition of comprehensive testing for the most studied drug-eluting stent in the world and reinforcing the CYPHER(R) Sirolimus-eluting coronary stent's reputation for efficacy and safety. The follow-up procedure was broadcast live during the 2009 meeting of the Latin America Society of Interventional Cardiology (SOLACI, Rio de Janeiro - Brazil).

In a history of impressive CYPHER(R) stent data announcements at ESC in Stockholm, Marie Claude Morice, M.D., Institut Cardiovasculaire Paris Sud, had presented the initial results of the highly successful RAVEL trial, the first CYPHER(R) stent randomized trial, at the Annual Congress of the European Society of Cardiology in 2001. And this year at ESC in 2010, the results of the 10-Year Follow-up of the first-ever patient to be treated with CYPHER(R) Drug-eluting stent are discussed during Cordis Hands-On Tutorials sessions.

Professor Eduardo Sousa, M.D., who led the team carrying out the first-in-human trial in 1999 and the 10-year follow-up tests in 2009 in Sao Paolo, Brazil, said, "We are very pleased with these results. This historic follow-up has revealed a sustained anti-proliferative effect of the CYPHER(R) stent by both angiography (in-stent late lumen loss of 0.10mm at 9 months as compared to 0.11 at 48 months) and IVUS examination (in stent % of obstruction of 1% at 4 months and 1,2,4, and 9 years). In addition, the ten-year OCT assessment revealed a complete coverage of over 90% of the analyzed struts. This is an impressive outcome and a testament to the efficacy of the CYPHER(R) stent."

Marie Claude Morice, M.D., who led the initial RAVEL trial presented to the European Society of Cardiology in 2001, explained, "The CYPHER(R) Sirolimus-eluting coronary stent was the first of its kind and was a major advance over bare-metal stents. A key trial showing the efficacy of CYPHER(R) stent found that up to 5 years after receiving the stent, the risk of restenosis of the artery is reduced by 60 - 70% compared to an uncoated stent. It is also the longest-studied drug-eluting stent, with over 200 medical trials having been carried out and 155,000 patients observed. These trials, from the initial RAVEL trial in 2001 to this latest ten-year follow-up, have proven the CYPHER(R) stent's safety and effectiveness."

Campbell Rogers, M.D., Chief Scientific Officer and Global Head R&D at Cordis, said, "We continue to be gratified by the outstanding performance of CYPHER(R) compared with other drug-eluting stents. The breadth of clinical safety and efficacy data and the long-term follow-up data on patient outcomes associated with the CYPHER(R) stent are unmatched by the competition. These historic long term results with the CYPHER(R) stent join ever-growing datasets demonstrating superiority of the CYPHER(R) stent over other newer DES competitors in diverse patient and lesion subsets and establish CYPHER(R) stent as the gold standard treatment for patients with coronary disease undergoing PCI."

Notes to Editors:

CYPHER(R) sirolimus-eluting coronary stent in detail

The CYPHER(R) stent releases a unique anti-inflammatory and anti-proliferative-type medicine, sirolimus, into the artery wall over a period of 90 days. The sirolimus helps limit the overgrowth of normal cells while the artery heals. The CYPHER(R) stent has a unique closed-cell design that allows the medicine to be distributed more evenly across the treated area and that helps to keep the arteries open and the blood flowing to the heart, reducing the chance of re-intervention in the treated area. Eighty percent (80%) of the sirolimus is released during the first 30 days. The rest is released by the end of 90 days.

About CYPHER(R) stent studies

The CYPHER(R) stent is the most studied drug-eluting stent in the world, it has a proven safety profile out to 10 years and has been used in nearly 4 million patients worldwide. Today, with more than 9.000 citations on PubMed, CYPHER(R) Sirolimus-eluting coronary stent is recognized as having the most in depth clinical data, which marked it out as the most effective drug-eluting stent available today with a safety profile presenting minimal risks. CYPHER's(R) body of clinical evidence is completely unmatched by any other drug-eluting stent. The CYPHER(R) stent has consistently proven to control late loss across all vessel sizes and across a broad patient population, even in the most complex types of patients such as patients with diabetes and acute myocardial infarction. In fact, the CYPHER(R) stent has shown more than 70% risk reduction in target lesion revascularization (TLR) when compared with bare metal stents.

About the RAVEL trial

In 2000, patients were enrolled in the RAVEL Trial, the first multi-center, randomized, double-blind, trial in history for drug-eluting stents. The primary objective of RAVEL was the safety and effectiveness of the CYPHER(R) Sirolimus-eluting stent in reducing angiographic in stent late loss (at 6-month follow-up) in de novo native coronary artery lesions as compared to the uncoated BX VELOCITY(TM) balloon-expandable stent. The trial was conducted in 15 centers in Europe and 4 in Latin American and presented by Dr Marie Claude Morice at the Annual Congress of the European Society of Cardiology in Stockholm on 4th September 2001. The results from this trial surpassed expectations, demonstrating virtual elimination of neointimal in-stent proliferation with no measurable late loss (-0.01mm), a binary angiographic restenosis rate of 0%, and no acute or late stent thrombosis.

The above addressed timelines at one view 1999 Cordis initiates the first clinical investigation of a drug-eluting stent. The First-In-Human trial, a safety and feasibility study is conducted in Sao Paolo/Brazil with Dr. Eduardo Sousa, and Rotterdam/The Netherlands with Dr. Patrick Serruys 2000 Cordis embarks on the first multicenter, double-blind, randomized, drug-eluting stent trial in history - RAVEL 2001 Dr. Marie-Claude Morice presents the initial results of the highly successful RAVEL trial, the first CYPHER(R) stent randomized trial, at the Annual Congress of the European Society of Cardiology in 2001 2009 Dr. Eduardo Sousa, who led the team carrying out the first-in-human trial in 1999 initiated the 10-year follow-up tests in 2009 in Sao Paolo, Brazil with the first patient ever treated with CYPHER(R) 2010 Results of the ten-year CYPHER(R) Sirolimus-eluting coronary stent follow-up are published

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson & Johnson company, has been a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease.


'/>"/>
SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cordis Unveils Next Generation CoCr Coronary Stent
2. OrthoAccel Technologies Announces Full-Market Release of AcceleDent, a New Technology to Shorten Treatment Time in Braces
3. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
4. Bionovo Announces Reverse Stock Split
5. Unilife Corporation Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2010
6. Vision Facilities Management Announces Real-Time ECRI Integration
7. Yongye International Announces Opening of New Production Facility
8. Nigerian Association of Pharmacists and Pharmaceutical Scientists in America (NAPPSA) Announces Prime Vendor Agreement with H. D. Smith
9. Millennium Laboratories Announces New Chief Operating Officer David Cohen
10. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
11. Misonix Announces New Distribution Agreement for Russia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):